WO2008002676A3 - Compositions de biaryle et procédés de modulation d'une cascade de kinases - Google Patents

Compositions de biaryle et procédés de modulation d'une cascade de kinases Download PDF

Info

Publication number
WO2008002676A3
WO2008002676A3 PCT/US2007/015273 US2007015273W WO2008002676A3 WO 2008002676 A3 WO2008002676 A3 WO 2008002676A3 US 2007015273 W US2007015273 W US 2007015273W WO 2008002676 A3 WO2008002676 A3 WO 2008002676A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
methods
kinase cascade
biaryl
compositions
Prior art date
Application number
PCT/US2007/015273
Other languages
English (en)
Other versions
WO2008002676A2 (fr
WO2008002676A9 (fr
Inventor
David G Hangauer Jr
Original Assignee
Kinex Pharmaceuticals Llc
David G Hangauer Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/480,174 external-priority patent/US7968574B2/en
Priority to DK07810102.9T priority Critical patent/DK2041071T3/da
Priority to CA2656564A priority patent/CA2656564C/fr
Priority to JP2009518322A priority patent/JP5564251B2/ja
Priority to CN200780031980XA priority patent/CN101595084B/zh
Priority to ES07810102.9T priority patent/ES2500165T3/es
Application filed by Kinex Pharmaceuticals Llc, David G Hangauer Jr filed Critical Kinex Pharmaceuticals Llc
Priority to AU2007265373A priority patent/AU2007265373B2/en
Priority to EP07810102.9A priority patent/EP2041071B1/fr
Priority to SI200731516T priority patent/SI2041071T1/sl
Publication of WO2008002676A2 publication Critical patent/WO2008002676A2/fr
Publication of WO2008002676A3 publication Critical patent/WO2008002676A3/fr
Publication of WO2008002676A9 publication Critical patent/WO2008002676A9/fr
Priority to IL196168A priority patent/IL196168A/en
Priority to IL242374A priority patent/IL242374A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

L'invention concerne des composés et des procédés permettant de moduler un ou plusieurs composants d'une cascade de kinases.
PCT/US2007/015273 2006-06-29 2007-06-29 Compositions de biaryle et procédés de modulation d'une cascade de kinases WO2008002676A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SI200731516T SI2041071T1 (sl) 2006-06-29 2007-06-29 Biarilni sestavki in postopki za moduliranje kinazne kaskade
EP07810102.9A EP2041071B1 (fr) 2006-06-29 2007-06-29 Compositions de biaryle et procédés de modulation d'une cascade de kinases
JP2009518322A JP5564251B2 (ja) 2006-06-29 2007-06-29 キナーゼカスケードを調節するためのビアリール組成物および方法
CN200780031980XA CN101595084B (zh) 2006-06-29 2007-06-29 用于调整激酶级联的二芳基组合物和方法
ES07810102.9T ES2500165T3 (es) 2006-06-29 2007-06-29 Composiciones de biarilo y métodos para modular una cascada de quinasas
DK07810102.9T DK2041071T3 (da) 2006-06-29 2007-06-29 Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
AU2007265373A AU2007265373B2 (en) 2006-06-29 2007-06-29 Biaryl compositions and methods for modulating a kinase cascade
CA2656564A CA2656564C (fr) 2006-06-29 2007-06-29 Compositions de biaryle et procedes de modulation d'une cascade de kinases
IL196168A IL196168A (en) 2006-06-29 2008-12-25 Use of baryryl compounds to prepare drugs for the treatment of kinase-mediated disorders
IL242374A IL242374A (en) 2006-06-29 2015-10-29 Baryl compounds and their pharmaceutical preparations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/480,174 US7968574B2 (en) 2004-12-28 2006-06-29 Biaryl compositions and methods for modulating a kinase cascade
US11/480,174 2006-06-29
US92349607P 2007-04-13 2007-04-13
US60/923,496 2007-04-13

Publications (3)

Publication Number Publication Date
WO2008002676A2 WO2008002676A2 (fr) 2008-01-03
WO2008002676A3 true WO2008002676A3 (fr) 2008-05-02
WO2008002676A9 WO2008002676A9 (fr) 2008-07-03

Family

ID=38821063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015273 WO2008002676A2 (fr) 2006-06-29 2007-06-29 Compositions de biaryle et procédés de modulation d'une cascade de kinases

Country Status (5)

Country Link
DK (1) DK2041071T3 (fr)
ES (1) ES2500165T3 (fr)
IL (1) IL242374A (fr)
PT (1) PT2041071E (fr)
WO (1) WO2008002676A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7300931B2 (en) 2004-12-28 2007-11-27 Kinex Pharmaceuticals, Llc Compositions for treating cell proliferation disorders
AU2007265373B2 (en) 2006-06-29 2013-02-21 Atnx Spv, Llc Biaryl compositions and methods for modulating a kinase cascade
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US8124605B2 (en) 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
CN105796568A (zh) 2007-10-20 2016-07-27 阿西纳斯公司 用于调控激酶级联的药物组合物及其使用方法
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基－雜芳基衍生物及其使用方法
WO2011129936A2 (fr) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions et procédés pour la prévention et le traitement du cancer
EP2590946B1 (fr) 2010-07-05 2015-02-18 Merck Patent GmbH Dérivés de bipyridyl utiles pour le traitement de maladies induites par des kinases
US9926273B2 (en) * 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (fr) 2013-01-15 2021-04-20 Incyte Holdings Corp Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim
WO2014209034A1 (fr) 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Dérivés de biaryle en tant qu'agonistes de gpr120
WO2015027124A1 (fr) 2013-08-23 2015-02-26 Incyte Corporation Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
EP3191449B1 (fr) 2014-09-10 2020-07-01 GlaxoSmithKline Intellectual Property Development Limited Composés utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
MY181913A (en) 2014-09-10 2021-01-14 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
KR20240038149A (ko) 2017-04-26 2024-03-22 바실리어 파마슈티카 인터내셔널 리미티드 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정
CA3074831A1 (fr) 2017-09-07 2019-03-14 Athenex HK Innovative Limited Formes solides de 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN113461665B (zh) * 2020-03-31 2023-05-19 成都赜灵生物医药科技有限公司 二芳基衍生物及其制备方法和用途
EP4302831A1 (fr) 2022-07-04 2024-01-10 Trifarma S.p.A. Procédé de synthèse de tirbanibulin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079197A1 (fr) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinases n-terminales c-jun (jnk) et autres proteineskinases
US6538960B1 (en) * 1999-07-09 2003-03-25 Sony Corporation Magneto-optical recording medium having a metal heat dispersion layer
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004011427A2 (fr) * 2002-07-31 2004-02-05 Smithkline Beecham Corporation Benzanilides substitues utilises en tant que modulateurs du recepteur ccr5
US20040242572A1 (en) * 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
WO2006071960A2 (fr) * 2004-12-28 2006-07-06 Kinex Pharmaceuticals, Llc Compositions et procedes de traitement de troubles de la proliferation cellulaire

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US20030130209A1 (en) 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
AU2002336864B2 (en) 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538960B1 (en) * 1999-07-09 2003-03-25 Sony Corporation Magneto-optical recording medium having a metal heat dispersion layer
WO2002079197A1 (fr) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinases n-terminales c-jun (jnk) et autres proteineskinases
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004011427A2 (fr) * 2002-07-31 2004-02-05 Smithkline Beecham Corporation Benzanilides substitues utilises en tant que modulateurs du recepteur ccr5
US20040242572A1 (en) * 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
WO2006071960A2 (fr) * 2004-12-28 2006-07-06 Kinex Pharmaceuticals, Llc Compositions et procedes de traitement de troubles de la proliferation cellulaire
US20060160800A1 (en) * 2004-12-28 2006-07-20 Hangauer David G Jr Compositions and methods of treating cell proliferation disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 14, no. 4, 2004, pages 983 - 988 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002470813, Database accession no. BRN:7392869 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002470814, Database accession no. BRN:9721347 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002470815, Database accession no. BRN: 9670273 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002470816, Database accession no. BRN: 543268 *
EUR. J. MED. CHEM. CHIM. THER., vol. 39, no. 1, 2004, pages 11 - 26 *
J. MED. CHEM, vol. 38, no. 23, 1995, pages 4693 - 4703 *
J. MED. CHEM., vol. 11, no. 5, 1968, pages 963 *

Also Published As

Publication number Publication date
PT2041071E (pt) 2014-09-23
DK2041071T3 (da) 2014-09-01
WO2008002676A2 (fr) 2008-01-03
ES2500165T3 (es) 2014-09-30
WO2008002676A9 (fr) 2008-07-03
IL242374A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
WO2008002676A3 (fr) Compositions de biaryle et procédés de modulation d'une cascade de kinases
WO2009009041A3 (fr) Compositions et procédés permettant de moduler une cascade de kinases
WO2008002674A3 (fr) Compositions bicycliques et procédés de modulation d'une cascade de kinases
WO2008014008A3 (fr) Compositions et procédés pour moduler l'angiogenèse
WO2008112939A3 (fr) Composition et procédé pour préparer des composés oligo-benzamide
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2007093627A3 (fr) Composition biocide
WO2007017423A3 (fr) Composition pharmaceutique
WO2007075847A3 (fr) Activateurs de glucokinase
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2008067219A3 (fr) Modulateurs quinazolinones de tgr5
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
WO2007109254A3 (fr) Compositions polypeptidiques stabilisées
WO2008157356A3 (fr) Formulations d'anticorps
WO2009077443A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2007087575A3 (fr) Compositions et procedes destines au traitement de l'hypertension pulmonaire
WO2009077500A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2006078886A3 (fr) Composes et compositions utilises comme modulateurs de la voie de signalisation wnt
ZA200804026B (en) Compositions and methods for modulating hemostasis
WO2007042288A3 (fr) Composes saveur kokumi et utilisation de ceux-ci
IL201064A0 (en) Janus kinase inhibitor compounds, compositions comprising the same and uses thereof
AU2008203254A1 (en) Compositions of phosphodiesterase type IV inhibitors
AU2008266094A8 (en) Stabilized thrombin compositions
WO2008011176A3 (fr) Composés inhibiteurs de kinase de chaîne légère de myosine, compositions et méthodes d'emploi correspondantes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780031980.X

Country of ref document: CN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2656564

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 196168

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009518322

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007265373

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007810102

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 416/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007265373

Country of ref document: AU

Date of ref document: 20070629

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810102

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 242374

Country of ref document: IL